biotech / news / / scanx.trade
Sun Pharmaceutical Industries Limited has received comprehensive clinical updates on two significant drug candidates in its pipeline.
Fibromun's Phase II trials in soft tissue sarcoma and glioblastoma did not meet primary endpoints.
KEY POINTS
- Survival benefit was observed in glioblastoma patients with limited alkylating agent exposure in GLIOSTAR trial.
- Nidlegy achieved complete pathological response in 52.60% of basal cell carcinoma patients in the Duncan study.
- Regulatory alignment with FDA enables Nidlegy’s continued US approval pathway pending ongoing Phase III results.
- New Phase III registrational trials for both Fibromun and Nidlegy are scheduled to initiate in 2026.
COMPANIES
Summarized by Newsio from scanx.trade. How we summarize →